

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/701,844
				Filing Date	November 4, 2003
				First Named Inventor	JACKSON, W. James
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	1	of	3	Attorney Docket Number	2479.0040002/EJH/C-K

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	NPL36	BATTEIGER, B.E., <i>et al.</i> , "Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis," <i>J. Gen. Microbiol.</i> 139:2965-2972, SGM (1993)		
	NPL37	BORK, P., "Go hunting in sequence databases but watch out for the traps," <i>Trends Genet.</i> 12:425-427, Elsevier Science Ltd. (October 1996)		
	NPL38	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Res.</i> 10:398-400, Cold Spring Harbor Laboratory Press (April 2000)		
	NPL39	BRENNER, S.E., "Errors in genome annotation," <i>Trends Genet.</i> 15:132-133, Elsevier Science Ltd.(April 1999)		
	NPL40	BUSH, R.M., and EVERETT, K.D.E., "Molecular evolution of the <i>Chlamydiaceae</i> ," <i>Int. J. Syst. Evol. Microbiol.</i> 51:203-220, IUMS (January 2001)		
	NPL41	CLYNE, J.M., <i>et al.</i> , "A Rapid Chemiluminescent DNA Hybridization Assay for the Detection of <i>Chlamydia Trachomatis</i> ," <i>J. Biolumin. Chemilumin.</i> 4:357-366, John Wiley & Sons, Ltd. (1989)		
	NPL42	DOERKS, T., <i>et al.</i> "Protein annotation: detective work for function prediction," <i>Trends Genet.</i> 14:248-250, Elsevier Science Ltd. (June 1998)		
	NPL43	KRIEG, A.M., "Therapeutic potential of Toll-like receptor 9 activation," <i>Nature Rev. Drug Discov.</i> 5:471-484, Nature Publishing Group (June 2006)		
	NPL44	MYGIND, P.H., <i>et al.</i> , "Membrane proteins PmpG and PmpH are major constituents of <i>Chlamydia trachomatis</i> L2 outer membrane complex," <i>FEMS Microbiol. Lett.</i> 186:163-169, Elsevier Science B.V. (May 2000)		
	NPL45	NCBI Entrez, GenBank Report, Accession No. ABB22785, Halse, T.A., <i>et al.</i> (First entered October 2005 and last revised August 2006)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/701,844
				Filing Date	November 4, 2003
				First Named Inventor	JACKSON, W. James
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	2	of	3	Attorney Docket Number	2479.0040002/EJH/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL46	NGO, J.T., <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox—Future Work," in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr., K.M., and Le Grand, S.M., eds., Birkhäuser, Boston, MA, pp. 492-495 (1994)	
	NPL47	PEIPERT, J.F., "Genital Chlamydial Infections," <i>N. Engl. J. Med.</i> 349:2424-2430, Massachusetts Medical Society (December 2003)	
	NPL48	SHAW, A.C., <i>et al.</i> , "Comparative proteome analysis of <i>Chlamydia trachomatis</i> serovar A, D, and L2," <i>Proteomics</i> 2:164-186, Wiley-VCH Verlag GmbH (February 2002)	
	NPL49	SKOLNICK, J., and FETROW, J.S., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18:34-39, Elsevier Science Ltd. (January 2000)	
	NPL50	SMITH, J.A., "Analysis of Proteins," in <i>Short Protocols in Molecular Biology 3rd ed.</i> , Ausubel, F.M., <i>et al.</i> , eds. John Wiley & Sons, Inc., United States (1997)	
	NPL51	SMITH, T.F., and ZHANG, X., "The challenges of genome sequence annotation or "The devil is in the details," <i>Nature Biotechnol.</i> 15:1222-1223, Nature America, Inc. (November 1997)	
	NPL52	STEPHENS, R.S., <i>et al.</i> , "Genome Sequence of an Obligate Intracellular Pathogen of Humans: <i>Chlamydia trachomatis</i> ," <i>Science</i> 282:754-759, American Association for the Advancement of Science (October 1998)	
	NPL53	SU, H., <i>et al.</i> , "Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of <i>Chlamydia trachomatis</i> genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection," <i>Vaccine</i> 13:1023-1032, Elsevier Science Ltd. (1995)	
	NPL54	TANZER, R.J., and HATCH, T.P., "Characterization of Outer Membrane Proteins in <i>Chlamydia trachomatis</i> LGV Serovar L2," <i>J. Bacteriol.</i> 183:2686-2690, American Society of Microbiology (April 2001)	
	NPL55	TUFFREY, M., <i>et al.</i> , "Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of <i>Chlamydia trachomatis</i> by prior immunization with recombinant serovar L1 major outer-membrane protein," <i>J. Gen. Microbiol.</i> 138:1707-1715, SGM (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.